Check­Mate-451: Bris­tol-My­ers’ Op­di­vo — plus Yer­voy — fails PhI­II com­bo lung can­cer study, the lat­est in a se­ries of set­backs

Bris­tol-My­ers Squibb $BMY is be­com­ing well prac­ticed at dis­ap­point­ing in­vestors with their R&D strat­e­gy for lung can­cer.

Af­ter the mar­ket closed Mon­day the phar­ma gi­ant re­port­ed that their Phase III tri­al match­ing Op­di­vo and their CT­LA-4 drug Yer­voy for Check­Mate-451 failed on the pri­ma­ry end­point for over­all sur­vival. Re­searchers were study­ing the com­bi­na­tion as a main­te­nance ther­a­py for small cell lung can­cer af­ter a first round of chemo, and this was one of the late-stage stud­ies that an­a­lysts have been wait­ing for.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER